Greater Cannabis Company (GCAN) Free Cash Flow (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Free Cash Flow came in at -$4376.0 in Q1 2026, up 60.77% year-on-year from -$2721.9 in Q1 2025, and up 81.87% quarter-over-quarter from -$24140.0 in Q4 2025.
Greater Cannabis Company (GCAN) Free Cash Flow (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$4376.0 for Q1 2026.
- On a quarterly basis, Free Cash Flow rose 60.77% year-over-year to -$4376.0 in Q1 2026; TTM through Mar 2026 was -$53374.0, a 35.78% increase from a year earlier, with the FY2025 full-year figure at -$60153.0, up 45.06% from the prior year.
- Free Cash Flow advanced to -$4376.0 in Q1 2026 per GCAN's latest filing, from -$24140.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4376.0 in Q1 2026 and bottomed at -$56392.0 in Q2 2022.
- The 5-year median for Free Cash Flow is -$19064.0 (2022), against an average of -$22628.3.
- Across the five-year window, Free Cash Flow soared 84.96% in 2024 and plunged 391.25% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at -$19064.0 in 2022, then sank by 71.39% to -$32673.0 in 2023, then surged by 84.96% to -$4914.0 in 2024, then sank by 391.25% to -$24140.0 in 2025, then soared by 81.87% to -$4376.0 in 2026.
- Per Business Quant, the three latest GCAN Free Cash Flow figures stand at -$4376.0 (Q1 2026), -$24140.0 (Q4 2025), and -$5357.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | -4,376.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,376.00 |
| Mar 31, 2026 | -4,376.00 |
| Dec 31, 2025 | -24,140.00 |
| Dec 31, 2025 | -24,140.00 |
| Sep 30, 2025 | -5,357.00 |
| Sep 30, 2025 | -5,357.00 |
| Jun 30, 2025 | -19,501.00 |
| Jun 30, 2025 | -19,501.00 |
| Mar 31, 2025 | -11,155.00 |
| Mar 31, 2025 | -11,155.00 |
| Dec 31, 2024 | -4,914.00 |
| Dec 31, 2024 | -4,914.00 |
| Sep 30, 2024 | -18,034.00 |
| Sep 30, 2024 | -18,034.00 |
| Jun 30, 2024 | -49,007.00 |
| Jun 30, 2024 | -49,007.00 |
| Mar 31, 2024 | -37,536.00 |
| Mar 31, 2024 | -37,536.00 |
| Dec 31, 2023 | -32,673.00 |
| Dec 31, 2023 | -32,673.00 |